NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class (Ascending) | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
16729-0276-68 | 16729-0276 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | March 25, 2014 | In Use | |
25021-0231-20 | 25021-0231 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug. 15, 2018 | No Longer Used | |
50742-0496-26 | 50742-0496 | gemcitabine | GEMCITABINE | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 1, 2023 | In Use | |
50742-0497-53 | 50742-0497 | gemcitabine | GEMCITABINE | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 1, 2023 | In Use | |
50742-0498-05 | 50742-0498 | Gemcitabine | Gemcitabine | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 1, 2023 | In Use | |
25021-0223-20 | 25021-0223 | Cytarabine | Cytarabine | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | June 1, 2023 | In Use | |
25021-0229-05 | 25021-0229 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | June 1, 2023 | In Use | |
83774-0100-60 | 83774-0100 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb. 27, 2024 | In Use | |
83774-0101-12 | 83774-0101 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Feb. 27, 2024 | In Use | |
16729-0092-03 | 16729-0092 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | July 28, 2011 | In Use |
Found 10,000 results in 14 milliseconds — Export these results